{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001279704","name":"Cellectar Biosciences, Inc.","summary":"Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on cancer treatment using its proprietary phospholipid ether drug conjugate (PDC) platform. Its lead products include iopofosine I 131 (iodine-131 beta-emitter studied in Waldenstrom macroglobulinemia, multiple myeloma, and CNS lymphoma), CLR 125 (iodine-125 Auger-emitter in triple-negative breast cancer), and CLR 225 (actinium-225 alpha-emitter in solid tumors). The company develops phospholipid radioconjugates designed to deliver radioisotopes directly to cancer cells while limiting healthy tissue exposure.","people":[],"products":[{"name":"Iopofosine I 131","type":"platform","description":"Beta-emitting iodine-131 phospholipid radioconjugate studied in r/r Waldenstrom macroglobulinemia, multiple myeloma, CNS lymphoma, and pediatric cancers; granted FDA Breakthrough Therapy Designation for r/r WM."},{"name":"CLR 125 (CLR 121125)","type":"platform","description":"Iodine-125 Auger-emitting phospholipid radioconjugate in Phase 1b clinical study for relapsed/refractory triple-negative breast cancer."},{"name":"CLR 225 (CLR 121225)","type":"platform","description":"Actinium-225 alpha-emitting phospholipid radioconjugate showing activity in pancreatic, colorectal, and breast cancer animal models; Phase 1 study pending financing."},{"name":"PDC Delivery Platform","type":"platform","description":"Proprietary phospholipid ether drug conjugate platform designed to specifically target cancer cells and deliver radioisotopes or other payloads with reduced off-target effects."}],"partnerships":[{"partner_name":"University of Wisconsin-Madison","partnership_type":"development","description":"Conducted investigator-initiated Phase 1 study of iopofosine in combination with external beam radiation in recurrent head and neck cancer patients.","start_date":null},{"partner_name":"National Cancer Institute (NIH)","partnership_type":"development","description":"Provided approximately $2M SBIR grant partially funding the CLOVER-2 Phase 1b pediatric high grade glioma study.","start_date":null}],"affiliations":[],"origin":{"leaf":"bc15e9621f6c49cf5c157a1cb52f5c639a12b2807ffc9649573c66d7c2c928c3","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"a6cf0f11c89ec0571f76c1ab81bc983a3661a1c080e6273ade133a7c86254489","parent":"e032e39513397ea973a6a8dbaac5a2727139789ce016e1f13f0af805c8a10c9c","source":"0001104659-26-023167","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":490,"hourly_limit":500,"remaining":10,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}